Claudio A. Ferreira, M.D. graduated from the Medical University of Vassouras in Rio de Janeiro, Brazil. He completed two internships: his first in internal medicine at Santa Casa Hospital in Brazil and his second in general surgery at the M. L. King/Charles Drew University Medical Center in Los Angeles, California.

Subsequently, he performed his ophthalmology residency at the King-Drew/UCLA program in Los Angeles. Dr Ferreira completed two vitreoretinal fellowships: his first at the University of Virginia and his second at the Vitreoretinal Foundation in Memphis, Tennessee.

Dr. Ferreira is a vitreoretinal surgeon and specializes in retina, vitreous and diabetic eye diseases. He participated in the clinical trials of an earlier version of Lucentis called Avastin while working as a Clinical Instructor of Ophthalmology at the University of Virginia in 2004.  Avastin, which had been used previously by ophthalmologists on a trial basis, was replaced by it’s “new and improved” descendent, Lucentis in June, 2006. Dr. Ferreira converted to Lucentis immediately upon its FDA approval and was the first retinal surgeon to offer Lucentis to the patients of Southeastern Massachusetts. This treatment represents a significant advancement, as improvement of vision in patients with wet macular degeneration was almost unheard of prior to the discovery of Avastin and Lucentis.

He is a member of the American Academy of Ophthalmology, California Academy of Ophthalmology, Association for Research in Vision and Ophthalmology and the Brazilian society of Ophthalmology.

He practices in our Dartmouth, Fall River and Taunton offices.